>





A pre-blended laboratory reference standard pairing BPC-157 with TB-500 in a single vial. Lyophilized for convenience in comparative healing-axis assays.
The BPC / TB Blend pairs the 15-residue Body Protection Compound 157 (BPC-157, GEPPPGKPADDAGLV) with the 43-residue Thymosin Beta-4 fragment (TB-500). The two peptides are co-lyophilized at a fixed mass ratio for convenience in research protocols that screen tissue-repair pathways across multiple mechanisms simultaneously.
Each component meets ≥ 99% HPLC purity independently before blending. Vials are sealed under nitrogen and shipped cold-chain at −20 °C from our Kelowna facility.
Combinatorial in-vitro healing-axis assays, tendon-fibroblast outgrowth, angiogenesis (HUVEC tube-formation), and comparative musculoskeletal-repair protocols where both BPC-157 and TB-500 mechanisms are studied in parallel.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
| Parameter | Value |
|---|---|
| Sequence | GEPPPGKPADDAGLV (BPC-157) + SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (TB-500) |
| Molecular formula | Pre-blend |
| Molecular weight | Mixed (1419.55 + 4963.44 g/mol) |
| CAS number | Mixed (137525-51-0 / 77591-33-4) |
| Length | Pre-blend (15 + 43 residues) |
| Test | Specification |
|---|---|
| HPLC purity | ≥ 99.0% (lot LM-2630: ≥ 99.0% per component) |
| Mass confirmation | ESI-MS within 0.5 Da |
| Net peptide content | ≥ 80% by AAA |
| Endotoxin | < 0.5 EU/mg (LAL) |
| Bioburden | < 10 CFU/g |
| Residual TFA | < 1.0% |
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.
| Method | Result |
|---|---|
| RP-HPLC at 220 nm | ≥ 99.0% per component main peak |
| ESI-MS (positive) | Two peaks: 1419.6 + 4963.4 Da |
| Amino acid analysis | 82.1% net peptide |
| LAL endotoxin | < 0.05 EU/mg |
| Karl Fischer (water) | 2.8% w/w |
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632.
Goldstein AL et al. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429.
Chang CH et al. Pentadecapeptide BPC 157 enhances tendon outgrowth and cell migration. J Appl Physiol. 2011;110(3):774–780.
BPC-157 / TB-500 Blend reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-BPCTB-10, Lot 26-A031.